XIPERE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for XIPERE (XIPERE).
Triamcinolone acetonide is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and stabilizing lysosomal membranes. It also decreases vascular permeability and inhibits cytokine release.
| Metabolism | Primarily metabolized in the liver via CYP3A4. |
| Excretion | XIPERE (triamcinolone acetonide injectable suspension) is primarily eliminated via hepatic metabolism and subsequent renal excretion of metabolites. Approximately 40% of the dose is excreted renally as metabolites, with less than 5% as unchanged drug. Biliary/fecal excretion accounts for about 60% of the dose, mainly as metabolites. |
| Half-life | The terminal elimination half-life of triamcinolone acetonide following suprachoroidal administration is approximately 18 hours. This short half-life allows for sustained local effect with minimal systemic accumulation. |
| Protein binding | Triamcinolone acetonide is approximately 68% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | The volume of distribution for triamcinolone acetonide is approximately 1.4 L/kg, indicating extensive tissue distribution, consistent with its lipophilic nature. |
| Bioavailability | Following suprachoroidal injection, XIPERE provides local delivery with negligible systemic bioavailability. Systemic absorption is minimal, resulting in low plasma concentrations. No oral bioavailability data are applicable as it is not administered orally. |
| Onset of Action | Clinical effect (reduction in macular edema) is observed within 2 to 4 weeks following a single suprachoroidal injection of XIPERE. |
| Duration of Action | The duration of therapeutic effect is approximately 3 to 6 months after a single suprachoroidal injection. Repeat dosing may be considered based on clinical response. |
The recommended dose is 0.1 mL (containing 0.16 mg triamcinolone acetonide injectable suspension) administered by suprachoroidal injection to the affected eye(s) once every 3 months (every 12 weeks).
| Dosage form | SUSPENSION |
| Renal impairment | No dosage adjustment is required for patients with renal impairment. |
| Liver impairment | No formal studies have been conducted; however, triamcinolone acetonide is primarily metabolized by the liver. Use with caution in patients with severe hepatic impairment (Child-Pugh class C). |
| Pediatric use | Safety and efficacy in pediatric patients have not been established. |
| Geriatric use | No specific dosage adjustment is recommended for geriatric patients; however, consider the increased frequency of comorbidities and concomitant medications. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for XIPERE (XIPERE).
| Breastfeeding | Systemic corticosteroids are excreted in breast milk in low amounts (M/P ratio unknown for triamcinolone acetonide). Intraocular administration results in negligible systemic levels; however, caution is advised. No data on XIPERE specifically. |
| Teratogenic Risk | XIPERE (triamcinolone acetonide injectable suspension) is a corticosteroid. Systemic corticosteroids are associated with increased risk of orofacial clefts (first trimester) and intrauterine growth restriction (second/third trimester). Intraocular administration minimizes systemic exposure, but no adequate human data exist; risk cannot be excluded. |
■ FDA Black Box Warning
No FDA black box warning reported.
| Serious Effects |
["Ocular or periocular infections (including tuberculous, fungal, viral)","Hypersensitivity to triamcinolone acetonide or any excipients"]
| Precautions | ["Increased intraocular pressure (IOP) requiring monitoring","Cataract formation","Ocular infections (including fungal, bacterial, viral)","Posterior subcapsular cataract","Glaucoma progression","Systemic corticosteroid effects (e.g., adrenal suppression) with frequent use"] |
Loading safety data…
| Fetal Monitoring | Monitor intraocular pressure (IOP) regularly due to steroid-induced glaucoma. Assess for cataract formation. Fetal monitoring: ultrasound for growth restriction if systemic exposure suspected. No specific fetal monitoring required with standard ophthalmic use. |
| Fertility Effects | No human data. Animal studies with systemic corticosteroids may impair fertility, but relevance to intraocular administration is unknown. No known effect on fertility with single dose. |